LMPN Urologist, Dr. Stephen Beck, performs 100 Aquablation therapy cases

Last Updated on May 29, 2024 by Logansport Memorial Hospital

Logansport Memorial Hospital is pleased to share that Urologist and Surgeon Dr. Stephen Beck has completed over 100 Aquablation therapy cases, providing relief for men suffering with benign prostatic hyperplasia (BPH), a condition caused by an obstructive prostate.

BPH is a non-cancerous condition where the prostate has grown to be obstructive in some way. This can place pressure on a man’s bladder and urethra, causing problems with urination. If left untreated, BPH can cause significant health problems, including irreversible bladder or kidney damage, bladder stones, and incontinence. 1 in 2 men ages 51 to 60 have BPH, and the incidence increases every decade of life. 4
Whereas many BPH surgical treatments often force men to trade-off between symptom relief and side effects, Aquablation therapy is proven to offer predictable and reproducible outcomes while preserving sexual function and continence. (1,2,3) Aquablation therapy is a resective procedure, meaning that the prostate tissue causing symptoms is removed using a waterjet controlled by robotic precision. Aquablation therapy can be performed on prostates of all shapes and sizes.

“We are proud to achieve this milestone of 100 cases of Aquablation therapy,”said Dr. Stephen Beck, Urologist and Surgeon at Logansport Memorial Hospital. “It has been a great opportunity to offer a solution that provides long-lasting relief with lower risk to patients’ sexual function or continence.

Aquablation therapy helps provide relief without compromising quality of life, which is one of my highest priorities for my patients.”

Logansport Memorial President and CEO Tara McVay commented, “We want to offer treatment methods that our patients need right here, in our own community, so that they don’t need to travel outside of the region to receive care. When patients can stay close to home and receive care from their trusted providers, it takes a lot of stress out of the recovery process and allows the patient to focus on healing. Dr. Beck’s achievement of over 100 Aquablation therapy cases speaks volumes to how impactful this service has been for improving quality of life for our patients, allowing them to feel better and live better.”

For an appointment or to learn more about whether this is the right treatment option for you, call LMPN Urology at (574) 753-2222, located inside our Surgical Services office.

For more information on Logansport Memorial Hospital, visit LogansportMemorial.org. For more information on Aquablation therapy, visit Aquablation.com.

SOURCE: News release from Logansport Memorial Hospital

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image- guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon
experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Important Safety Information
All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a
frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon.

Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam® Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or
alternative therapies may sometimes be required. As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention: Anesthesia risk, Bladder or
prostate capsule perforation, Bladder neck contracture, Bleeding or blood in the urine, Bruising, Penile or pelvic pain, Irritative symptoms, which may include dysuria, urgency or frequency, Infection, Transurethral resection (TUR) syndrome, Electric shock/burn, Urethral damage causing false passage or
stricture, Rectal incontinence / perforation, Sexual dysfunction, including ejaculatory and erectile dysfunction, Incontinence or overactive bladder, Embolism, Urinary Retention
Rx Only
References:

1. Gilling et al. Five-year outcomes for Aquablation therapy compared to TURP: a randomized controlled trial in men with LUTS due to
   BPH Can J Urol 2022; 29(1):10960-10968.
2. Zorn KC, Bidair M, Trainer A, Arther A, Kramolowsky E, Desai M, et al. Aquablation therapy in large prostates (80–150 cc) for lower
   urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3- year trial results. BJUI Compass. 2022;3(2):130–138.
3. Bach, T, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb; 9(2): 603.
4. Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once
   daily. Clinical Interventions in Aging 2008:3(3)